These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18809819)

  • 61. Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings.
    Leisegang R; Maartens G; Hislop M; Regensberg L; Cleary S
    BMC Health Serv Res; 2010 Jul; 10 Suppl 1(Suppl 1):S3. PubMed ID: 20594369
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development.
    Morris BL; Scott CA; Wilkin TJ; Sax PE; Gulick RM; Freedberg KA; Schackman BR
    HIV Clin Trials; 2012; 13(1):1-10. PubMed ID: 22306583
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of routine viral load monitoring in low- and middle-income countries: a systematic review.
    Barnabas RV; Revill P; Tan N; Phillips A
    J Int AIDS Soc; 2017 Nov; 20 Suppl 7(Suppl 7):. PubMed ID: 29171172
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.
    Maggiolo F; Colombo GL; Di Matteo S; Bruno GM; Astuti N; Di Filippo E; Masini G; Bernardini C
    Patient Relat Outcome Meas; 2015; 6():53-60. PubMed ID: 25733942
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis.
    Estill J; Aubrière C; Egger M; Johnson L; Wood R; Garone D; Gsponer T; Wandeler G; Boulle A; Davies MA; Hallett TB; Keiser O;
    AIDS; 2012 Jul; 26(11):1403-13. PubMed ID: 22421243
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.
    Sendi PP; Bucher HC; Harr T; Craig BA; Schwietert M; Pfluger D; Gafni A; Battegay M
    AIDS; 1999 Jun; 13(9):1115-22. PubMed ID: 10397543
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.
    Walensky RP; Ciaranello AL; Park JE; Freedberg KA
    Clin Infect Dis; 2010 Jul; 51(1):85-92. PubMed ID: 20482371
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Low-cost assays for monitoring HIV infected individuals in resource-limited settings.
    Balakrishnan P; Iqbal HS; Shanmugham S; Mohanakrishnan J; Solomon SS; Mayer KH; Solomon S
    Indian J Med Res; 2011 Dec; 134(6):823-34. PubMed ID: 22310816
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Modified Dynabeads method for enumerating CD4+ T-lymphocyte count for widespread use in resource-limited situations.
    Bi X; Gatanaga H; Tanaka M; Honda M; Ida S; Kimura S; Oka S
    J Acquir Immune Defic Syndr; 2005 Jan; 38(1):1-4. PubMed ID: 15608516
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy.
    Hyle EP; Sax PE; Walensky RP
    JAMA Intern Med; 2013 Oct; 173(18):1746-8. PubMed ID: 23978894
    [No Abstract]   [Full Text] [Related]  

  • 71. Impact of a borderless sample transport network for scaling up viral load monitoring: results of a geospatial optimization model for Zambia.
    Nichols BE; Girdwood SJ; Crompton T; Stewart-Isherwood L; Berrie L; Chimhamhiwa D; Moyo C; Kuehnle J; Stevens W; Rosen S;
    J Int AIDS Soc; 2018 Dec; 21(12):e25206. PubMed ID: 30515997
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reflecting the real value of health care resources in modelling and cost-effectiveness studies-The example of viral load informed differentiated care.
    Revill P; Walker S; Cambiano V; Phillips A; Sculpher MJ
    PLoS One; 2018; 13(1):e0190283. PubMed ID: 29293611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Medication costs associated with early initiation of antiretroviral therapy.
    Grimes RM; Grimes DE
    AIDS Care; 2018 Dec; 30(12):1512-1516. PubMed ID: 30021449
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda.
    Babigumira JB; Castelnuovo B; Stergachis A; Kiragga A; Shaefer P; Lamorde M; Kambugu A; Muwanga A; Garrison LP
    PLoS One; 2011 Mar; 6(3):e18193. PubMed ID: 21464895
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients.
    Noubary F; Hughes MD
    Stat Med; 2010 Aug; 29(18):1932-46. PubMed ID: 20680986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia.
    Bikilla AD; Jerene D; Robberstad B; Lindtjørn B
    Cost Eff Resour Alloc; 2009 Jul; 7():13. PubMed ID: 19615069
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy.
    Johansson KA; Robberstad B; Norheim OF
    AIDS Res Ther; 2010 Jan; 7(1):3. PubMed ID: 20180966
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lifetime cost of human immunodeficiency virus-related health care.
    Hurley SF; Kaldor JM; Gardiner S; Carlin JB; Assunção RM; Evans DB
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(4):371-8. PubMed ID: 8673546
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa.
    Paltiel AD; Zheng A; Weinstein MC; Gaynes MR; Wood R; Freedberg KA; Sax PE; Walensky RP
    Open Forum Infect Dis; 2017; 4(2):ofx081. PubMed ID: 28680903
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost deal for HIV tests.
    Lancet; 2004 Jan; 363(9405):301. PubMed ID: 14753213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.